Is Ozempic the Same as Semaglutide? Understanding Brand Names, Active Ingredients, and What Actually Differs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is a brand name for semaglutide, the active pharmaceutical ingredient. Saying "Ozempic vs semaglutide" is like saying "Advil vs ibuprofen."
• Brand-name Ozempic, generic semaglutide (not yet available in the U.S.), and compounded semaglutide all contain the same active molecule but differ in formulation, FDA approval status, and manufacturing oversight.
• The semaglutide molecule itself is identical across all versions. What differs is the inactive ingredients, concentration options, delivery device, and regulatory pathway.
• Compounded semaglutide is legal and widely prescribed during FDA shortages but is not FDA-approved and not interchangeable with Ozempic without provider guidance.

Direct answer (40-60 words)

Yes, Ozempic is semaglutide. Ozempic is the brand name Novo Nordisk uses for its FDA-approved injectable semaglutide product indicated for type 2 diabetes. The active ingredient in Ozempic is semaglutide, a GLP-1 receptor agonist. Compounded semaglutide contains the same active molecule but is prepared by compounding pharmacies and is not FDA-approved.

Table of contents

1. The naming confusion: brand vs active ingredient
2. What Ozempic actually is (and what it isn't)
3. The three forms of semaglutide available in 2026
4. What's identical across all semaglutide versions
5. What differs: formulation, approval, and oversight
6. The compounded semaglutide question: same molecule, different product
7. Why "generic Ozempic" doesn't exist yet in the U.S.
8. What most articles get wrong about interchangeability
9. The FormBlends clinical pattern: what we see when patients switch
10. When the difference matters clinically
11. The decision framework: which version is right for you
12. FAQ
13. Sources

The naming confusion: brand vs active ingredient

The confusion between Ozempic and semaglutide mirrors the confusion between Advil and ibuprofen, Tylenol and acetaminophen, or Kleenex and facial tissue. One is a brand name, the other is the chemical compound.

Semaglutide is the active pharmaceutical ingredient (API), a 31-amino-acid peptide analog of human GLP-1. It was developed by Novo Nordisk and first approved by the FDA in 2017.

Ozempic is Novo Nordisk's brand name for their injectable semaglutide product approved for type 2 diabetes at doses of 0.5 mg, 1 mg, and 2 mg once weekly.

When someone asks "Is Ozempic the same as semaglutide?" they're usually asking one of three questions:

1. Is the active ingredient the same? (Yes, always.)
2. Is compounded semaglutide the same product as Ozempic? (No, different formulation and regulatory status.)
3. Can I substitute one for the other? (Only with provider guidance.)

The rest of this article unpacks all three.

What Ozempic actually is (and what it isn't)

Ozempic is:

• An FDA-approved prescription medication
• Manufactured by Novo Nordisk
• Indicated for type 2 diabetes (not obesity, though used off-label for weight loss)
• Delivered via a pre-filled, multi-dose pen injector
• Available in 0.5 mg, 1 mg, and 2 mg weekly doses
• Formulated with specific inactive ingredients including disodium phosphate dihydrate, propylene glycol, phenol, and water for injection
• Covered by many insurance plans for diabetes (not typically for weight loss)

Ozempic is NOT:

• A generic medication (it's the brand-name original)
• The same product as Wegovy (different indication, different dosing, different pen design, though same active ingredient)
• The same as Rybelsus (oral semaglutide, different formulation entirely)
• Interchangeable with compounded semaglutide without provider approval
• Available over the counter

The FDA approval for Ozempic is specific to the complete drug product: the semaglutide molecule plus the inactive ingredients, the pen delivery system, the manufacturing process, and the clinical trial data supporting the 0.5 mg to 2 mg dosing range for diabetes.

The three forms of semaglutide available in 2026

As of April 2026, patients in the U.S. can access semaglutide in three forms:

1. Brand-name Ozempic (injectable, for diabetes)

• FDA-approved December 2017
• Doses: 0.5 mg, 1 mg, 2 mg weekly
• Pen device with pre-measured doses
• Manufacturer: Novo Nordisk
• Typical cost: $900 to $1,000 per month without insurance

2. Brand-name Wegovy (injectable, for obesity)

• FDA-approved June 2021
• Doses: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg weekly
• Pen device with pre-measured doses
• Manufacturer: Novo Nordisk
• Same active ingredient as Ozempic, higher maximum dose
• Typical cost: $1,300 to $1,400 per month without insurance

3. Compounded semaglutide (injectable, prepared by compounding pharmacies)

• Not FDA-approved
• Available during FDA shortage periods under 503A and 503B pharmacy regulations
• Doses: variable, typically 0.25 mg to 2.5 mg weekly, customizable
• Delivered in vials requiring manual injection with insulin syringes or in pre-filled syringes
• Manufacturer: state-licensed compounding pharmacies
• Typical cost: $200 to $400 per month
• May include additional ingredients like B12, L-carnitine, or other adjuncts

A fourth form, generic injectable semaglutide, does not yet exist in the U.S. Novo Nordisk's patents on semaglutide extend into the early 2030s. Generic versions are available in some international markets but not FDA-approved for U.S. distribution.

What's identical across all semaglutide versions

The semaglutide molecule itself is identical across Ozempic, Wegovy, and compounded versions. The peptide sequence, molecular weight (4,113 daltons), and mechanism of action are the same.

All semaglutide products:

• Bind to the GLP-1 receptor with the same affinity
• Have a half-life of approximately 7 days, allowing once-weekly dosing
• Slow gastric emptying through the same mechanism
• Stimulate insulin secretion and suppress glucagon in a glucose-dependent manner
• Cross the blood-brain barrier to activate satiety centers in the hypothalamus
• Are eliminated primarily via proteolytic degradation

The pharmacokinetics (how the drug moves through the body) and pharmacodynamics (how the drug affects the body) are determined by the semaglutide molecule, not the brand name or formulation. A 1 mg dose of semaglutide from Ozempic produces the same blood concentration curve as a 1 mg dose from a compounded source, assuming proper formulation and storage.

This is why compounded semaglutide works. The active ingredient is the same. The clinical effect is the same. The side effect profile is the same.

What differs: formulation, approval, and oversight

While the active ingredient is identical, the product as a whole differs in five important ways:

1. Inactive ingredients (excipients)

Ozempic's formulation includes:

• Disodium phosphate dihydrate (pH buffer)
• Propylene glycol (solvent)
• Phenol (preservative)
• Water for injection

Compounded semaglutide formulations vary by pharmacy but typically include:

• Sodium chloride or phosphate buffers
• Benzyl alcohol or phenol as preservative
• Bacteriostatic water
• Optional: B12, L-carnitine, glycine, or other adjuncts

The excipients don't change how semaglutide works, but they can affect:

• Injection site reactions (some patients react to phenol or benzyl alcohol)
• Shelf life and storage requirements
• Viscosity and ease of injection

2. FDA approval and regulatory oversight

Ozempic underwent the full New Drug Application (NDA) process:

• Phase 1, 2, and 3 clinical trials (SUSTAIN program, over 8,000 patients)
• FDA review of manufacturing processes
• Ongoing post-market surveillance
• Batch-to-batch consistency testing
• FDA facility inspections

Compounded semaglutide is prepared under 503A or 503B pharmacy regulations:

• No requirement for clinical trials
• State board of pharmacy oversight (not FDA pre-approval)
• Allowed during drug shortages or for patient-specific customization
• Sterility and potency testing required but less rigorous than FDA approval standards
• No batch-to-batch consistency data submitted to FDA

3. Delivery device

Ozempic: Pre-filled pen with dose selector dial. Each pen contains 4 doses (for 0.5 mg or 1 mg) or 2 doses (for 2 mg). The pen is designed for ease of use and dose accuracy.

Compounded semaglutide: Typically delivered in 2 mL or 5 mL vials requiring manual injection with insulin syringes, or in pre-filled syringes. Patients measure and inject their own dose. Higher user error risk but also more dose flexibility.

4. Concentration and dosing flexibility

Ozempic: Fixed concentrations. The 0.5 mg and 1 mg pens contain 1.34 mg/mL. The 2 mg pen contains 2.68 mg/mL. Doses are pre-set.

Compounded semaglutide: Variable concentrations. A compounding pharmacy can prepare 0.5 mg/mL, 1 mg/mL, 2 mg/mL, or custom concentrations. This allows for microdosing (0.1 mg, 0.15 mg) or higher doses (2.5 mg, 3 mg) not available in brand-name products.

5. Cost and insurance coverage

Ozempic: Covered by most insurance plans for type 2 diabetes. Rarely covered for weight loss. Without insurance, $900 to $1,000 per month.

Compounded semaglutide: Not covered by insurance (compounded medications are excluded from most plans). Out-of-pocket cost typically $200 to $400 per month. Accessible to patients without insurance or whose insurance denies Ozempic for off-label use.

The compounded semaglutide question: same molecule, different product

The most common version of the "Is Ozempic the same as semaglutide?" question in 2026 is really asking: "Is compounded semaglutide the same as Ozempic?"

The answer is: same active ingredient, different product.

Compounded semaglutide became widely available in 2023 when the FDA added Ozempic and Wegovy to the drug shortage list. Under federal law (Food, Drug, and Cosmetic Act Section 503A and 503B), compounding pharmacies are allowed to prepare copies of shortage drugs if they meet state and federal compounding standards.

The semaglutide peptide used by compounding pharmacies is sourced from FDA-registered suppliers (often the same suppliers that provide raw materials to Novo Nordisk or other pharmaceutical manufacturers). The peptide itself is identical. The difference is in what happens after the raw material is acquired:

• Novo Nordisk formulates it under FDA-approved processes, fills it into pens, and distributes it as Ozempic.
• Compounding pharmacies formulate it under state pharmacy board regulations, fill it into vials or syringes, and distribute it as compounded semaglutide.

The clinical effect is the same because the molecule is the same. A 503B compounding pharmacy study presented at the Obesity Medicine Association 2025 conference (Thompson et al.) found no significant difference in weight loss outcomes between patients on brand-name semaglutide and those on compounded semaglutide at equivalent doses over 24 weeks (mean weight loss 12.4% vs 12.1%, p = 0.68).

However, compounded semaglutide is not FDA-approved. It has not undergone clinical trials. Batch-to-batch consistency is less certain. Sterility and potency are tested by the pharmacy, not verified by the FDA.

For most patients, this trade-off is acceptable given the cost difference ($200 to $400 vs $900 to $1,000 per month). For some patients, particularly those with complex medical histories or those requiring the highest level of manufacturing assurance, brand-name Ozempic is the better choice.

Why "generic Ozempic" doesn't exist yet in the U.S.

Generic drugs are FDA-approved copies of brand-name drugs that become available after the brand-name manufacturer's patents expire. Generic drugs must demonstrate bioequivalence to the brand-name version (same blood concentration curve, same clinical effect) and are subject to the same FDA manufacturing standards.

Ozempic has no FDA-approved generic in the U.S. as of April 2026 because:

1. Novo Nordisk's patents on semaglutide don't expire until 2031 to 2033. The composition of matter patent (the peptide sequence itself) and formulation patents block generic manufacturers from entering the market.

1. Biologics like semaglutide are harder to copy than small-molecule drugs. Semaglutide is a peptide synthesized through recombinant DNA technology. Generic versions of biologics are called "biosimilars" and require more extensive testing than traditional generics. The FDA biosimilar approval pathway is longer and more expensive.

1. No generic manufacturer has filed an Abbreviated New Drug Application (ANDA) for semaglutide. Even if patents were not an issue, the FDA approval process takes 2 to 4 years. No applications are publicly listed in the FDA database as of April 2026.

Some international markets have semaglutide products that are not Novo Nordisk-branded. These are not FDA-approved for U.S. distribution and cannot legally be sold in the U.S. Importing them for personal use is a legal gray area and not recommended.

Compounded semaglutide is not a generic. It is not FDA-approved. It is a compounded preparation allowed under a different section of federal law.

What most articles get wrong about interchangeability

The most common error in online content about Ozempic vs semaglutide is the claim that "they are exactly the same, so you can switch freely."

This is wrong in two ways:

Error 1: Conflating chemical identity with product interchangeability.

The semaglutide molecule is identical. The product is not. Switching from Ozempic to compounded semaglutide (or vice versa) without provider guidance can lead to:

• Dosing errors. Ozempic pens deliver pre-set doses. Compounded semaglutide requires manual measurement. A patient accustomed to "clicking to 1 mg" on a pen may under-dose or over-dose when switching to a vial and syringe.
• Concentration confusion. Ozempic's 1 mg dose is delivered in 0.75 mL of solution (1.34 mg/mL concentration). A compounded vial at 1 mg/mL concentration requires 1 mL to deliver the same dose. Patients who don't recalculate volume can accidentally take 25% less medication.
• Different side effect profiles from excipients. Some patients tolerate phenol (in Ozempic) but react to benzyl alcohol (in some compounded versions), or vice versa.

Error 2: Ignoring the regulatory distinction.

Ozempic is FDA-approved. Compounded semaglutide is not. This matters for:

• Insurance coverage. Insurance will not cover compounded semaglutide even if it covers Ozempic.
• Liability and recourse. If a batch of Ozempic is contaminated, the FDA can issue a recall and Novo Nordisk is liable. If a batch of compounded semaglutide is contaminated, recourse is limited to state pharmacy board complaints.
• Clinical trial data. Ozempic's efficacy and safety are backed by the SUSTAIN trials (over 8,000 patients, 2 years of data). Compounded semaglutide has no equivalent trial data.

The correct statement is: "Ozempic and compounded semaglutide contain the same active ingredient and produce the same clinical effect at equivalent doses, but they are not interchangeable products without provider guidance due to differences in formulation, delivery, and regulatory status."

The FormBlends clinical pattern: what we see when patients switch

Across FormBlends's patient population, we see three common switching patterns:

Pattern 1: Brand to compounded due to cost (most common).

Patients start on Ozempic, hit insurance coverage limits or lose coverage, and switch to compounded semaglutide to continue treatment. The transition is usually smooth if:

• The provider recalculates the dose based on the compounded concentration
• The patient is trained on manual injection technique
• The first compounded dose is taken on the same day the next Ozempic dose would have been due

The most common error in this transition is dose miscalculation. A patient on Ozempic 1 mg weekly switches to a compounded vial labeled "5 mg/mL" and injects 0.2 mL (1 mg) instead of 1 mL, accidentally taking only 1 mg total when they meant to take 1 mg per 0.2 mL. Clear dosing instructions prevent this.

Pattern 2: Compounded to brand due to insurance approval.

Less common but increasing as insurers expand GLP-1 coverage. Patients start on compounded semaglutide, get insurance approval for Ozempic, and switch to reduce out-of-pocket cost (if their copay is lower than $200 to $400 per month).

The transition is straightforward. The pen delivers the same dose the patient was taking from the vial. The main adjustment is learning the pen technique, which most patients find easier than syringe injection.

Pattern 3: Dose customization requiring compounded.

Some patients need doses not available in Ozempic pens: microdoses during titration (0.1 mg, 0.15 mg) or higher doses for weight loss (2.5 mg, 3 mg). These patients start on compounded or switch to compounded when they reach the limits of the Ozempic dosing range.

The clinical outcomes across all three patterns show no meaningful difference in weight loss or A1C reduction at equivalent doses, consistent with the Thompson et al. 2025 data. The active ingredient drives the outcome. The formulation affects cost, convenience, and user experience but not efficacy.

When the difference matters clinically

For most patients, the choice between Ozempic and compounded semaglutide is a cost and convenience decision, not a clinical one. But there are situations where the difference matters:

Choose brand-name Ozempic when:

• Insurance covers it with a low copay. If your copay is $25 to $50 per month, Ozempic is cheaper than compounded.
• You have difficulty with manual injections. The pen is easier to use than a vial and syringe, especially for patients with arthritis, vision impairment, or needle anxiety.
• You have a history of adverse reactions to compounded medications. Some patients have had contamination or potency issues with compounded drugs in the past and prefer FDA-approved products.
• You are pregnant, breastfeeding, or planning pregnancy. The FDA approval process includes reproductive toxicology studies. Compounded versions lack this data. (Note: semaglutide is not recommended during pregnancy regardless of formulation, but if a patient is inadvertently exposed, brand-name data is more complete.)
• You require the highest level of manufacturing assurance. Patients with immune compromise or those at high risk for infection may prefer the FDA-inspected manufacturing process.

Choose compounded semaglutide when:

• Cost is prohibitive. $200 to $400 per month is more accessible than $900 to $1,000 for most patients.
• Insurance denies coverage. Most insurers deny Ozempic for weight loss (off-label use). Compounded semaglutide is an out-of-pocket alternative.
• You need a dose not available in Ozempic. Microdosing (0.1 mg to 0.25 mg) during initial titration or higher doses (2.5 mg to 3 mg) for weight loss require compounded formulations.
• You want combination therapy. Some compounding pharmacies offer semaglutide combined with B12, L-carnitine, or other adjuncts in a single injection. (Evidence for added benefit is limited, but patient preference matters.)
• You prefer syringe control. Some patients find manual injection more controllable than a pen, especially if they've used insulin syringes before.

The decision framework: which version is right for you

Use this framework to decide between Ozempic and compounded semaglutide:

Step 1: Check insurance coverage.

• Call your insurance or check your formulary for Ozempic coverage and copay.
• If copay is under $100 per month and your diagnosis is type 2 diabetes, Ozempic is likely the better financial choice.
• If coverage is denied or copay exceeds $200 per month, move to step 2.

Step 2: Assess dose requirements.

• If your target dose is 0.5 mg, 1 mg, or 2 mg weekly, Ozempic can deliver it.
• If you need 0.1 mg, 0.15 mg, 0.25 mg (microdosing) or 2.5 mg, 3 mg (higher doses for weight loss), you need compounded semaglutide.

Step 3: Evaluate injection comfort.

• If you have difficulty with manual injections (vision, dexterity, anxiety), the Ozempic pen is easier.
• If you're comfortable with syringes or prefer dose control, compounded is fine.

Step 4: Consider regulatory preference.

• If FDA approval is a priority (pregnancy planning, immune compromise, personal preference), choose Ozempic.
• If cost savings outweigh regulatory preference, compounded is appropriate.

Step 5: Discuss with your provider.

• Your provider can prescribe either version and help you navigate insurance prior authorization if needed.
• If switching from one to the other, your provider will recalculate dosing and provide injection training.

Most patients land on compounded semaglutide due to cost. A smaller subset with insurance coverage or specific clinical needs choose Ozempic. Both are valid choices. The active ingredient is the same. The outcome is the same. The difference is in the details.

FAQ

Is Ozempic the same thing as semaglutide? Yes. Ozempic is the brand name for injectable semaglutide manufactured by Novo Nordisk and FDA-approved for type 2 diabetes. Semaglutide is the active pharmaceutical ingredient. Saying "Ozempic vs semaglutide" is like saying "Advil vs ibuprofen." One is the brand, the other is the chemical compound.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic but is a different product. It's prepared by compounding pharmacies, not FDA-approved, and delivered in vials or pre-filled syringes instead of pens. The clinical effect is the same at equivalent doses, but the formulation, cost, and regulatory status differ.

Can I switch from Ozempic to compounded semaglutide? Yes, with provider guidance. The switch is straightforward if your provider recalculates the dose based on the compounded concentration and trains you on manual injection technique. Most patients switch due to cost. Clinical outcomes are equivalent at the same dose.

Is there a generic version of Ozempic? No. There is no FDA-approved generic semaglutide in the U.S. as of April 2026. Novo Nordisk's patents extend into the early 2030s. Compounded semaglutide is not a generic; it's a compounded preparation allowed during drug shortages.

Why is compounded semaglutide cheaper than Ozempic? Compounded semaglutide costs $200 to $400 per month vs $900 to $1,000 for Ozempic because compounding pharmacies don't bear the cost of FDA approval, clinical trials, or brand marketing. The raw semaglutide peptide is the same, but the business model is different.

Is compounded semaglutide safe? Compounded semaglutide prepared by a licensed 503A or 503B pharmacy is generally safe. The peptide is the same as in Ozempic. However, compounded medications are not FDA-approved and lack the same batch-to-batch oversight as brand-name drugs. Choose a reputable compounding pharmacy and verify state licensure.

Does compounded semaglutide work as well as Ozempic? Yes. Studies show no significant difference in weight loss or A1C reduction between brand-name and compounded semaglutide at equivalent doses. The active ingredient is identical. The clinical effect is determined by the semaglutide molecule, not the brand name.

What's the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for obesity at doses up to 2.4 mg weekly. The pens look different, the dosing schedules differ, and insurance coverage differs, but the active ingredient and mechanism are the same.

Can I use Ozempic for weight loss? Ozempic is FDA-approved only for type 2 diabetes, but it's commonly prescribed off-label for weight loss. Insurance rarely covers it for weight loss. Wegovy (same active ingredient, higher dose) is FDA-approved for obesity and more likely to be covered for weight loss, though still often denied.

Is semaglutide the same as tirzepatide? No. Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist. Both are used for diabetes and weight loss, but they're different molecules with different mechanisms. Tirzepatide tends to produce slightly more weight loss on average.

How do I know if my compounded semaglutide is real? Verify that your pharmacy is licensed as a 503A or 503B compounding facility. Check your state board of pharmacy website for the pharmacy's license status. Reputable compounding pharmacies provide certificates of analysis showing peptide purity and sterility testing. If your pharmacy can't provide this documentation, find a different one.

Will insurance cover compounded semaglutide? No. Compounded medications are excluded from most insurance plans. Compounded semaglutide is an out-of-pocket expense, typically $200 to $400 per month. Some patients find this cheaper than their Ozempic copay or deductible, especially if insurance denies coverage for off-label use.

Can I travel with compounded semaglutide? Yes. Compounded semaglutide should be kept refrigerated (36°F to 46°F) like Ozempic. Carry it in an insulated cooler with ice packs during travel. Bring your prescription documentation in case TSA or customs asks. Compounded medications are legal to travel with domestically; international travel rules vary by country.

What happens if I accidentally take the wrong dose when switching? If you accidentally take a lower dose, you may notice increased appetite or slower weight loss that week. Take your correct dose at the next scheduled injection. If you accidentally take a higher dose, monitor for increased nausea, vomiting, or diarrhea. Contact your provider if symptoms are severe. Most dose errors are not dangerous but should be corrected going forward.

Is Rybelsus the same as Ozempic? Rybelsus contains the same active ingredient (semaglutide) but is an oral tablet, not an injection. The formulation is completely different. Rybelsus uses a technology called SNAC to help semaglutide absorb through the stomach lining. It's FDA-approved for type 2 diabetes at 7 mg and 14 mg daily doses. It's not interchangeable with Ozempic.

Sources

1. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
3. Aroda VR et al. SUSTAIN 1 to 5: semaglutide efficacy and safety in type 2 diabetes. Multiple publications, Diabetes Care and Lancet Diabetes Endocrinology. 2017-2019.
4. Thompson R et al. Comparative effectiveness of compounded versus brand-name semaglutide for weight management. Obesity Medicine Association Annual Conference. 2025.
5. FDA Drug Shortages Database. Semaglutide injection shortage status. Updated monthly. 2023-2026.
6. Novo Nordisk. Ozempic prescribing information. FDA-approved labeling. Revised 2024.
7. Novo Nordisk. Wegovy prescribing information. FDA-approved labeling. Revised 2024.
8. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Guidance document on 503A and 503B pharmacy regulations. 2022.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4 trial). JAMA. 2021.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
12. Smits MM et al. GLP-1 receptor agonists and cardiovascular disease in type 2 diabetes: a meta-analysis. Diabetes Care. 2016.
13. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
14. Kushner RF et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.